• About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Partners
  • Technology
    • CD30 CAR-T Cell Therapy
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • Manufacturing
  • Pipeline
    • TT11 CD30 CAR Ts
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

What are you looking for?

Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
  • About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Partners
  • Technology
    • CD30 CAR-T Cell Therapy
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • Manufacturing
  • Pipeline
    • TT11 CD30 CAR Ts
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

    tessathe2

  • All
  • Career Opportunities
  • home-featured
  • news-pressrelease
  • news-videos
  • Singapore-Product Development
  • US – Information Technology
    • home-featured
    • news-pressrelease
    • PR 2019

    Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020

    State-of-the-art manufacturing facility will support clinical and commercial production of cell therapies for thousands of…

    Continue Reading
  • ABOUT US
  • TECHNOLOGY
  • PIPELINE
  • PRESS RELEASES & EVENTS
  • CAREERS
  • CONTACT US

SITEMAP          PRIVACY POLICY

© 2020 Tessa Therapeutics Ltd. All rights reserved.